Seth Klarman: portfolio of Baupost Group

Seth Klarman leads the Baupost Group, which follows a value approach and looks for securities trading below their estimated worth.

Source: 13F filing with the US Securities and Exchange Commission dated Feb 14, 2017. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

You are looking at Q4 2016. Go to the latest filing (Q3 2026)

7.6B USDQ4 2016
Total value of stock positions
7.6B USD
Positions
42
Share of the ten largest
72.4%

The ten largest positions Q4 2016

  1. Cheniere Energy Inc 11.8%▼ −22.0%
  2. Viasat Inc 11.5%▲ +14.1%
  3. Synchrony Financial 9.9%▲ +17.6%
  4. Allergan PLC 9.5%▲ +71.5%
  5. Twenty First Centy Fox Inc 7.1%▲ +50.1%
  6. Pbf Energy Inc 5.8%unchanged
  7. Dell Technologies 4.8%unchanged
  8. Antero Res Corp 4.5%unchanged
  9. Theravance Biopharma Inc 3.9%▲ +26.2%
  10. Northstar Asset Mgmt Group I 3.7%▲ +88.7%
Total value of stock positions per quarter, Q2 2013 to Q3 2026 (peak 12.7B USD).
Choose a quarter (54 filings)

All positions Q4 2016

Positions Q4 2016 per 13F filing, 9 of 9
Symbol Weight Shares Reported value Change Held since
Viasat Inc 11.5% 13,158,137 871.3M USD +14.1% increased Q2 2013 or earlier 15 quarters
Theravance Biopharma Inc 3.9% 9,273,991 295.7M USD +26.2% increased Q2 2014 11 quarters
Twenty First Centy Fox Inc 7.1% 19,137,469 536.6M USD +50.1% increased Q3 2015 6 quarters
Allergan PLC 9.5% 3,432,603 720.9M USD +71.5% increased Q1 2016 4 quarters
Credit Accep Corp Mich 0.7% 244,400 53.2M USD +144.4% increased Q2 2016 3 quarters
SYF Synchrony Financial 9.9% 20,665,000 749.5M USD +17.6% increased Q3 2016 2 quarters
Northstar Asset Mgmt Group I 3.7% 18,705,000 279.1M USD +88.7% increased Q3 2016 2 quarters
Northstar Rlty Fin Corp 2.9% 14,577,134 220.8M USD +165.1% increased Q3 2016 2 quarters
Colony Cap Inc 1.9% 6,959,017 140.9M USD +56.5% increased Q3 2016 2 quarters

“Held since”: the first quarter from which the position appears in the 13F filing at every quarter end. It first appears at the end of that quarter – the filing gives neither date nor price, and trading between two quarter ends is not visible. “Or earlier”: the position was already in the first available filing (or the first one after a gap in filings). After a change of the security identifier (e.g. a renaming) the start may appear later.

Plus 2 positions in convertible bonds and bonds worth 72.4M USD as reported – not included in the weights.

Convertible bonds and bonds, principal amount as reported. They are not stock positions and therefore do not count towards the weights.

  • Theravance Inc principal 46.2M USD 38.4M USD
  • Theravance Biopharma Inc principal 30.0M USD 34.1M USD

Breakdown by sector

  • Financials 9.9%
  • Technology 4.8%
  • Health Care 3.3%
  • Industrials 0.2%
  • not in our coverage 81.8%

Sectors only for stocks we cover; the rest is grouped under “not in our coverage”.

How to read this page

  • Weight: a position’s share of the total value of all reported stock positions in this quarter – options and bonds are not counted.
  • Change: number of shares compared with the previous quarter. After a stock split we convert the previous quarter’s share count so that a split does not look like an increase; if a possible split cannot be confirmed, “–” is shown.
  • Reported value: value of the position at quarter end as reported by the investor. The portfolio may have changed since then.

All superinvestor portfolios Screener: stocks held by superinvestors

↑ ↓ select · Enter open · Esc close